Dyne Therapeutics, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-06-22: Reporting owner Greene Barry E; Form 4; Security Stock option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-05: Reporting owner HURWITZ EDWARD; Form 4; Security Stock option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-05: Reporting owner Lubner David Charles; Form 4; Security Stock option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-05: Reporting owner Rhodes Jason P; Form 4; Security Stock option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
DYN insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-22 | Greene Barry E Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +57,463 57,463 owned after | $20.87 exercise price | $20.87 | 2026-06-23 |
| 2026-06-05 | HURWITZ EDWARD Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,152 35,152 owned after | $17.04 exercise price | $17.04 | 2026-06-09 |
| 2026-06-05 | Lubner David Charles Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,152 35,152 owned after | $17.04 exercise price | $17.04 | 2026-06-09 |
| 2026-06-05 | Rhodes Jason P Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,152 35,152 owned after | $17.04 exercise price | $17.04 | 2026-06-09 |
| 2026-06-05 | Kersten Dirk Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,152 35,152 owned after | $17.04 exercise price | $17.04 | 2026-06-09 |
| 2026-06-05 | Incerti Carlo Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,152 35,152 owned after | $17.04 exercise price | $17.04 | 2026-06-09 |
| 2026-06-05 | Stehman-Breen Catherine Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,152 35,152 owned after | $17.04 exercise price | $17.04 | 2026-06-09 |
| 2026-06-05 | Posner Brian S Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,152 35,152 owned after | $17.04 exercise price | $17.04 | 2026-06-09 |
| 2026-02-12 | Cox John Director, Officer (CEO & President) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +285,000 285,000 owned after | $16.00 exercise price | $16.00 | 2026-02-17 |
| 2026-02-12 | Kerr Douglas Officer (Chief Medical Officer) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,000 130,000 owned after | $16.00 exercise price | $16.00 | 2026-02-17 |
| 2026-02-12 | Friedl-Naderer Johanna Officer (Chief Commercial Officer) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $16.00 exercise price | $16.00 | 2026-02-17 |
| 2026-02-12 | Lucera Erick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,000 105,000 owned after | $16.00 exercise price | $16.00 | 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |